A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

One year after being acquired by Global Alzheimer’s Platform Innovations, Tampa-based Axiom Brain Health has expanded its ...